MXPA05009011A - Metodo para tratar la enfermedad de parkinson en humanos por infusion intraputaminal de lineas de celulas gliales derivadas del factor neurotrofico. - Google Patents

Metodo para tratar la enfermedad de parkinson en humanos por infusion intraputaminal de lineas de celulas gliales derivadas del factor neurotrofico.

Info

Publication number
MXPA05009011A
MXPA05009011A MXPA05009011A MXPA05009011A MXPA05009011A MX PA05009011 A MXPA05009011 A MX PA05009011A MX PA05009011 A MXPA05009011 A MX PA05009011A MX PA05009011 A MXPA05009011 A MX PA05009011A MX PA05009011 A MXPA05009011 A MX PA05009011A
Authority
MX
Mexico
Prior art keywords
humans
disease
treatment
infused
neurotrophic factor
Prior art date
Application number
MXPA05009011A
Other languages
English (en)
Inventor
Greg Allen Gerhardt
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MXPA05009011A publication Critical patent/MXPA05009011A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a un metodo para tratar la enfermedad de Parkinson en humanos, en donde el factor neurotrofico de lineas de celulas gliales (FNDG) es cronicamente administrado directamente a uno o ambos putamenes de un humano en necesidad del mismo tratamiento. En un aspecto de la presente invencion, el FNDG es infundido directamente en uno o ambos putamenes a traves de uno o mas cateteres intraparenquimales residentes conectados a una bomba implantable.
MXPA05009011A 2003-02-24 2004-02-24 Metodo para tratar la enfermedad de parkinson en humanos por infusion intraputaminal de lineas de celulas gliales derivadas del factor neurotrofico. MXPA05009011A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44978903P 2003-02-24 2003-02-24
US10/784,547 US20040209810A1 (en) 2003-02-24 2004-02-23 Method of treating Parkinson's disease in humans by intraputaminal infusion of glial cell-line derived neurotrophic factor
PCT/US2004/005063 WO2004075720A2 (en) 2003-02-24 2004-02-24 Use of intraputaminal infused glial cell-line derived neurotrophic factor in the treatment of parkinson’s disease in humans

Publications (1)

Publication Number Publication Date
MXPA05009011A true MXPA05009011A (es) 2006-04-07

Family

ID=32930523

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009011A MXPA05009011A (es) 2003-02-24 2004-02-24 Metodo para tratar la enfermedad de parkinson en humanos por infusion intraputaminal de lineas de celulas gliales derivadas del factor neurotrofico.

Country Status (8)

Country Link
US (1) US20040209810A1 (es)
EP (1) EP1622636A2 (es)
JP (1) JP2006518747A (es)
AU (1) AU2004216251A1 (es)
CA (1) CA2516857A1 (es)
MX (1) MXPA05009011A (es)
PL (1) PL378360A1 (es)
WO (1) WO2004075720A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205772D0 (en) * 2002-03-12 2002-04-24 Gill Steven S Catheter
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US7815623B2 (en) * 2004-10-05 2010-10-19 Genzyme Corporation Stepped cannula
US9089667B2 (en) * 2005-08-23 2015-07-28 The Regents Of The University Of California Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery
BRPI0710800A2 (pt) * 2006-04-25 2012-01-17 Univ California administração de fatores de crescimento para o tratamento de distúrbios de snc
EP2023949A4 (en) * 2006-04-26 2009-08-26 Univ California COMPOSITIONS AND METHODS FOR THE DELIVERY OF NEUROTHERAPY OF HIGH MOLECULAR WEIGHT ENHANCED BY CONVECTION
PL2152346T3 (pl) * 2007-05-17 2016-04-29 Medgenesis Therapeutix Inc Cewnik do konwekcyjnie zwiększonej podaży leku z wyjmowanym usztywniającym elementem
ES2658626T3 (es) * 2009-02-12 2018-03-12 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de células gliales (GDNF) por inhibición de transcrito antisentido natural a GDNF
ES2363353B1 (es) * 2010-01-19 2012-02-22 Universidad De Sevilla Composición que comprende gdnf y tgf-beta1 y su uso para el tratamiento de una enfermedad neurológica.
EP2558154B1 (en) 2010-04-16 2020-06-17 ClearPoint Neuro, Inc. Mri surgical systems including mri-compatible surgical cannulae for transferring a substance to and/or from a patient
US9891296B2 (en) 2013-09-13 2018-02-13 MRI Interventions, Inc. Intrabody fluid transfer devices, systems and methods
WO2015059632A1 (en) * 2013-10-23 2015-04-30 Acadia Pharmaceuticals Inc. Treatment of a neurodegenerative disease or disorder
WO2017142698A1 (en) 2016-02-17 2017-08-24 MRI Interventions, Inc. Intrabody surgical fluid transfer assemblies with adjustable exposed cannula to needle tip length, related systems and methods
US11253237B2 (en) 2018-05-09 2022-02-22 Clearpoint Neuro, Inc. MRI compatible intrabody fluid transfer systems and related devices and methods
US11022664B2 (en) 2018-05-09 2021-06-01 Clearpoint Neuro, Inc. MRI compatible intrabody fluid transfer systems and related devices and methods
US11684750B2 (en) 2019-10-08 2023-06-27 Clearpoint Neuro, Inc. Extension tube assembly and related medical fluid transfer systems and methods
KR102519725B1 (ko) * 2022-06-10 2023-04-10 주식회사 하이 사용자의 인지 기능 상태를 식별하는 기법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU220795B1 (hu) * 1991-09-20 2002-05-28 Amgen Inc. Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére
JP2968840B2 (ja) * 1991-09-20 1999-11-02 サイナーゲン，インコーポレーテッド グリア由来神経栄養因子
US7069634B1 (en) * 1995-04-28 2006-07-04 Medtronic, Inc. Method for manufacturing a catheter
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6042549A (en) * 1996-03-22 2000-03-28 Seiko Epson Corporation Exercise intensity measuring device and exercise quantity measuring device

Also Published As

Publication number Publication date
US20040209810A1 (en) 2004-10-21
JP2006518747A (ja) 2006-08-17
WO2004075720A3 (en) 2004-11-11
PL378360A1 (pl) 2006-03-20
WO2004075720A2 (en) 2004-09-10
CA2516857A1 (en) 2004-09-10
AU2004216251A1 (en) 2004-09-10
EP1622636A2 (en) 2006-02-08

Similar Documents

Publication Publication Date Title
WO2006044115A3 (en) Method of treating parkinson's disease by convection-enhanced infusion of glial cell-line derived neurotrophic factor (gdnf) to the putamen
MXPA05009011A (es) Metodo para tratar la enfermedad de parkinson en humanos por infusion intraputaminal de lineas de celulas gliales derivadas del factor neurotrofico.
AU739944B2 (en) Nasal ventilation as a treatment for stroke
WO2003032815A3 (en) Medical device for delivering patches
WO2003089033A8 (en) Implantable drug delivery system responsive to intra-cardiac pressure
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
MXPA03006855A (es) Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion.
AU2001287187A1 (en) Method and devices for decreasing elevated pulmonary venous pressure
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
IL175141A0 (en) Method of therapy
HK1050847A1 (en) Treatment of congestive heart failure by pretreated autologous blood.
WO2004062470A3 (en) System and method for stimulation of a person’s brain stem
TW200607512A (en) Use of optically pure (S,S)-reboxetine in the manufacture of a medicament for the treatment or prevention of migraine headaches
WO2001097906A3 (en) Apparatus for treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion
BG106171A (en) Compositions and uses of et743 for treating cancer
TR200200620T2 (tr) Levosimendan farmasötik solüsyonları
PT2111868E (pt) Utilização de albumina humana terapêutica na preparação de um medicamento para o tratamento de doentes sofrendo de distúrbios cognitivos
BR0211400A (pt) Tratamento de distrofia muscular com células de sangue do cordão
SE0102147D0 (sv) New methods
PL376217A1 (en) Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics
MD1716B2 (en) Use of melatonin for treatment of patients dependent on benzodiazepine
IL141117A0 (en) Means for retaining transcutaneous catheters and needles in place
RU2285533C2 (ru) Способ введения хлористого кальция
EP1632235A3 (en) Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders
CN106859982A (zh) 医用保健型耳钉

Legal Events

Date Code Title Description
FG Grant or registration